Robert Burdette

Robert Burdette serves as a Contract Specialist responsible for managing the full lifecycle of federal acquisitions within a specialized pharmaceutical procurement environment. His role encompasses the development, solicitation, evaluation, and award of contracts for the manufacture of finished pharmaceutical preparations, ensuring compliance with federal acquisition regulations and agency mission objectives. He works closely with technical evaluators, legal advisors, and program managers to align procurement strategy with public health priorities, primarily handling competitive sealed bids and negotiated procurements under FAR Part 15. His expertise lies in navigating the complex regulatory landscape of drug manufacturing, including cGMP compliance and supply chain integrity requirements. While no specific contractor relationships are identifiable due to limited data, Burdette’s procurement patterns suggest consistent engagement with manufacturers holding appropriate FDA registrations and DEA licenses, particularly those with established quality assurance systems and validated production capabilities. His contracting approach emphasizes vendor performance history, technical capability, and regulatory adherence over price alone, fostering long-term partnerships with qualified suppliers capable of meeting stringent pharmaceutical standards. Burdette’s contracting activity shows a 100% preference for non-set-aside procurements, indicating a focus on open competition rather than socioeconomic set-asides such as 8(a), HUBZone, or SDVOSB programs. This reflects a mission-driven prioritization of product efficacy, regulatory compliance, and supply reliability over socioeconomic targeting, though he remains compliant with all statutory small business participation requirements. His primary focus is on NAICS 325412—Pharmaceutical Preparation Manufacturing—indicating deep specialization in the procurement of finished dosage forms, including tablets, capsules, injectables, and sterile solutions. He manages acquisitions requiring strict adherence to Good Manufacturing Practices, cold chain logistics, and batch traceability, demonstrating technical fluency in pharmaceutical quality systems and regulatory submissions under FDA oversight.